Citations (68)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
María Molina Vega, Araceli Muñoz-Garach & Francisco J. Tinahones. (2018) Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 14:2, pages 207-217.
Read now
Read now
Mikkel Z Ankarfeldt, Erpur Adalsteinsson, Rolf HH Groenwold, M Sanni Ali & Olaf H Klungel. (2017) A systematic literature review on the efficacy–effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs. Clinical Epidemiology 9, pages 41-51.
Read now
Read now
Philip A Levin, Hiep Nguyen, Eric T Wittbrodt & Seoyoung C Kim. (2017) Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes, Metabolic Syndrome and Obesity 10, pages 123-139.
Read now
Read now
G. Lozano-Ortega, S. Goring, H.A. Bennett, K. Bergenheim, C. Sternhufvud & J. Mukherjee. (2016) Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea. Current Medical Research and Opinion 32:5, pages 807-816.
Read now
Read now
Marc Evans, Stephen C. Bain & Jiten Vora. (2016) A systematic review of the safety of incretin-based therapies in type 2 diabetes. Expert Review of Endocrinology & Metabolism 11:2, pages 217-232.
Read now
Read now
L. Østergaard, Christian S. Frandsen & S. Madsbad. (2016) Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Review of Clinical Pharmacology 9:2, pages 241-265.
Read now
Read now
Xiao-Hui Guo. (2016) The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide. Current Medical Research and Opinion 32:1, pages 61-76.
Read now
Read now
Devesh Sennik, Fahad Ahmed & David Russell-Jones. (2012) Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 7:1, pages 15-26.
Read now
Read now
Franco Folli & Rodolfo Guardado Mendoza. (2011) Potential use of exenatide for the treatment of obesity. Expert Opinion on Investigational Drugs 20:12, pages 1717-1722.
Read now
Read now
K. Esposito, C. Mosca, C. Brancario, P. Chiodini, A. Ceriello & D. Giugliano. (2011) GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Current Medical Research and Opinion 27:8, pages 1519-1528.
Read now
Read now
Peggy Soule Odegard & Anthony DeSantis. (2009) Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 2, pages 135-144.
Read now
Read now
Articles from other publishers (57)
Lawrence Blonde, Guillermo E. Umpierrez, S. Sethu Reddy, Janet B. McGill, Sarah L. Berga, Michael Bush, Suchitra Chandrasekaran, Ralph A. DeFronzo, Daniel Einhorn, Rodolfo J. Galindo, Thomas W. Gardner, Rajesh Garg, W. Timothy Garvey, Irl B. Hirsch, Daniel L. Hurley, Kenneth Izuora, Mikhail Kosiborod, Darin Olson, Shailendra B. Patel, Rodica Pop-Busui, Archana R. Sadhu, Susan L. Samson, Carla Stec, William V. TamborlaneJr.Jr., Katherine R. Tuttle, Christine Twining, Adrian Vella, Priyathama Vellanki & Sandra L. Weber. (2022) American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocrine Practice 28:10, pages 923-1049.
Crossref
Crossref
Yujun Wan, Xiaojuan Xu, Robert G. Gilbert & Mitchell A. Sullivan. (2021) A Review on the Structure and Anti-Diabetic (Type 2) Functions of β-Glucans. Foods 11:1, pages 57.
Crossref
Crossref
Anastasia-Stefania Alexopoulos & John B. Buse. (2019) Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. Metabolism 98, pages 104-111.
Crossref
Crossref
Gaia Chiara Mannino, Francesco Andreozzi & Giorgio Sesti. (2019) Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine. Diabetes/Metabolism Research and Reviews 35:3, pages e3109.
Crossref
Crossref
Ioannis Avgerinos, Thomas Karagiannis, Konstantinos Malandris, Aris Liakos, Maria Mainou, Eleni Bekiari, David R. Matthews & Apostolos Tsapas. (2019) Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity and Metabolism 21:1, pages 188-193.
Crossref
Crossref
Ke SuChunmei LvZongwen JiYishu WangHaifeng Wang, Ying Bai & Yaping Liu. (2018) Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus. American Journal of Therapeutics 25:6, pages e609-e616.
Crossref
Crossref
Jagriti Upadhyay, Stergios A. Polyzos, Nikolaos Perakakis, Bindiya Thakkar, Stavroula A. Paschou, Niki Katsiki, Patricia Underwood, Kyung-Hee Park, Jochen Seufert, Eun Seok Kang, Elliot Sternthal, Asterios Karagiannis & Christos S. Mantzoros. (2018) Pharmacotherapy of type 2 diabetes: An update. Metabolism 78, pages 13-42.
Crossref
Crossref
Greer Waldrop, Jixin Zhong, Matthew Peters, Aditya Goud, Yin-Hsiu Chen, Stephen N. Davis, Bhramar Mukherjee & Sanjay Rajagopalan. (2018) Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis. Journal of Diabetes and its Complications 32:1, pages 113-122.
Crossref
Crossref
Matteo Monami, Ilaria Dicembrini, Besmir Nreu, Francesco Andreozzi, Giorgio Sesti & Edoardo Mannucci. (2017) Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. Acta Diabetologica 54:12, pages 1101-1114.
Crossref
Crossref
Huibiao Quan, Huachuan Zhang, Weiping Wei, Tuanyu Fang, Daoxiong Chen & Kaining Chen. (2017) A crossover study of the combination therapy of metformin and exenatide or biphasic insulin aspart 30 in overweight or obese patients newly diagnosed with type 2 diabetes mellitus. Experimental and Therapeutic Medicine 14:4, pages 3279-3287.
Crossref
Crossref
Julie A. Lovshin. (2017) Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. Canadian Journal of Diabetes 41:5, pages 524-535.
Crossref
Crossref
Marc Evans, Sayeed Achha & Cheryl Neslusan. (2017) Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK. Diabetes Therapy 8:5, pages 1175-1185.
Crossref
Crossref
Julie A. Lovshin. (2017) WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. Canadian Journal of Diabetes.
Crossref
Crossref
Sara F.L. Kirk, Tatyana A. Shamliyan & Maria Middleton. (2017) Glucagon-like peptide-1 agonists for weight loss in people with obesity. Obesity Medicine 5, pages 29-43.
Crossref
Crossref
Mirna S. Abd El Aziz, Melanie Kahle, Juris J. Meier & Michael A. Nauck. (2017) A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes, Obesity and Metabolism 19:2, pages 216-227.
Crossref
Crossref
Kaisa Miikkulainen, Antonio Caruso, Oliver Mast, Rongrong Zhang & Oleg Borisenko. (2016) Systematic literature review of use of blood glucose monitoring in phase III clinical studies of insulin analogs. BMC Endocrine Disorders 16:1.
Crossref
Crossref
Helene Bihan, Winda L. Ng, Dianna J. Magliano & Jonathan E. Shaw. (2016) Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review. Diabetes Research and Clinical Practice 121, pages 27-34.
Crossref
Crossref
Tiansheng Wang, Fei Wang, Junwen Zhou, Huilin Tang & Sharon Giovenale. (2016) Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials. Diabetes/Metabolism Research and Reviews 32:8, pages 843-857.
Crossref
Crossref
Crystal Man Ying Lee, Mark Woodward & Stephen Colagiuri. (2016) Triple therapy combinations for the treatment of type 2 diabetes – A network meta-analysis. Diabetes Research and Clinical Practice 116, pages 149-158.
Crossref
Crossref
Zhixia Li, Yuan Zhang, Xiaochi Quan, Zhirong Yang, Xiantao Zeng, Linong Ji, Feng Sun & Siyan Zhan. (2016) Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. PLOS ONE 11:5, pages e0154206.
Crossref
Crossref
Je-Yon Kim, Seungwon Yang, Jangik I. Lee & Min Jung Chang. (2016) Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. PLOS ONE 11:4, pages e0153502.
Crossref
Crossref
Martin J. Downes, Emilie K. Bettington, Jenny E. Gunton & Erika Turkstra. (2015) Triple therapy in type 2 diabetes; a systematic review and network meta-analysis. PeerJ 3, pages e1461.
Crossref
Crossref
Xihua Zhong, Tianyi Zhang, Yuzhou Liu, Xin Wei, Xinji Zhang, Yingyi Qin, Zhichao Jin, Qi Chen, Xiuqiang Ma, Rui Wang & Jia He. (2015) Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: A network meta-analysis. Diabetes Research and Clinical Practice 109:3, pages 451-460.
Crossref
Crossref
Jessica E. Potts, Laura J. Gray, Emer M. Brady, Kamlesh Khunti, Melanie J. Davies & Danielle H. Bodicoat. (2015) The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis. PLOS ONE 10:6, pages e0126769.
Crossref
Crossref
Chloe L. Edridge, Alison J. Dunkley, Danielle H. Bodicoat, Tanith C. Rose, Laura J. Gray, Melanie J. Davies & Kamlesh Khunti. (2015) Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies. PLOS ONE 10:6, pages e0126427.
Crossref
Crossref
Yehuda Handelsman, Zachary T. Bloomgarden, George Grunberger, Guillermo Umpierrez, Robert S. Zimmerman, Timothy S. Bailey, Lawrence Blonde, George A. Bray, A. Jay Cohen, Samuel Dagogo-Jack, Jaime A. Davidson, Daniel Einhorn, Om P. Ganda, Alan J. Garber, W. Timothy Garvey, Robert R. Henry, Irl B. Hirsch, Edward S. Horton, Daniel L. Hurley, Paul S. Jellinger, Lois Jovanovič, Harold E. Lebovitz, Derek LeRoith, Philip Levy, Janet B. McGill, Jeffrey I. Mechanick, Jorge H. Mestman, Etie S. Moghissi, Eric A. Orzeck, Rachel Pessah-Pollack, Paul D. Rosenblit, Aaron I. Vinik, Kathleen Wyne & Farhad Zangeneh. (2015) American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan – 2015. Endocrine Practice 21, pages 1-87.
Crossref
Crossref
Kira B. Harris & Delilah J. McCarty. (2014) Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism 6:1, pages 3-18.
Crossref
Crossref
Meera Shah & Adrian Vella. (2014) Effects of GLP-1 on appetite and weight. Reviews in Endocrine and Metabolic Disorders 15:3, pages 181-187.
Crossref
Crossref
Michaela Diamant, Luc Van Gaal, Bruno Guerci, Stephen Stranks, Jenny Han, Jaret Malloy, Marilyn K Boardman & Michael E Trautmann. (2014) Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. The Lancet Diabetes & Endocrinology 2:6, pages 464-473.
Crossref
Crossref
L van Bloemendaal, J S ten Kulve, S E la Fleur, R G Ijzerman & M Diamant. (2014) Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Journal of Endocrinology 221:1, pages T1-T16.
Crossref
Crossref
S. Liatis & K. Makrilakis. (2014) Glucagon-like peptide-1 receptor agonists vs. insulin in inadequately controlled patients with type 2 diabetes. Is this meta-analysis miscalculated?. Diabetes, Obesity and Metabolism 16:3, pages 284-284.
Crossref
Crossref
Paul L. McCormack. (2014) Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus. Drugs 74:3, pages 325-351.
Crossref
Crossref
J. E. Schopman, A. C. R. Simon, S. J. M. Hoefnagel, J. B. L. Hoekstra, R. J. P. M. Scholten & F. Holleman. (2014) The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes/Metabolism Research and Reviews 30:1, pages 11-22.
Crossref
Crossref
Baptist Gallwitz & Reinhard G. Bretzel. (2013) How Do We Continue Treatment in Patients With Type 2 Diabetes When Therapeutic Goals Are Not Reached With Oral Antidiabetes Agents and Lifestyle? Incretin versus insulin treatment. Diabetes Care 36:Supplement_2, pages S180-S189.
Crossref
Crossref
R. E. van Genugten, D. L. Möller‐Goede, D. H. van Raalte & M. Diamant. (2013) Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes. Diabetes, Obesity and Metabolism 15:7, pages 593-606.
Crossref
Crossref
Chinmay S. Marathe, Christopher K. Rayner, Karen L. Jones & Michael Horowitz. (2013) Glucagon-like peptides 1 and 2 in health and disease: A review. Peptides 44, pages 75-86.
Crossref
Crossref
Mary Hines & Katherine W. Lyseng-Williamson. (2013) Biphasic insulin aspart 30: a guide to its use in diabetes mellitus. Drugs & Therapy Perspectives 29:5, pages 135-140.
Crossref
Crossref
Andreas Liebl, Vinay Prusty, Paul Valensi, Ryuzo Kawamori, Jens Sandahl Christiansen, Andrew J. Palmer, Per Balschmidt, Robert Ligthelm & Viswanathan Mohan. (2012) Ten Years of Experience with Biphasic Insulin Aspart 30. Drugs 72:11, pages 1495-1520.
Crossref
Crossref
Bruce Bode. (2012) An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Research and Clinical Practice 97:1, pages 27-42.
Crossref
Crossref
Vanita R. Aroda, Robert R. Henry, Jenny Han, Wenying Huang, Mary Beth DeYoung, Tamara Darsow & Byron J. Hoogwerf. (2012) Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review. Clinical Therapeutics 34:6, pages 1247-1258.e22.
Crossref
Crossref
J. H. Best, K. Lavillotti, M. B. DeYoung & L. P. Garrison. (2011) The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review. Diabetes, Obesity and Metabolism 14:5, pages 387-398.
Crossref
Crossref
N. Kaimal, J. Schofield, A. Zaki, R. Patel, M. Sharma, E. Mccourt & K. E. Imtiaz. (2011) Effects of exenatide in poorly controlled type 2 diabetes*. QJM 105:4, pages 321-326.
Crossref
Crossref
Jack L. Leahy. (2012) Insulin Therapy in Type 2 Diabetes Mellitus. Endocrinology and Metabolism Clinics of North America 41:1, pages 119-144.
Crossref
Crossref
B. Vergès, C. Bonnard & E. Renard. (2011) Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes & Metabolism 37:6, pages 477-488.
Crossref
Crossref
Ronald M. Goldenberg. (2011) Management of Unmet Needs in Type 2 Diabetes Mellitus: The Role of Incretin Agents. Canadian Journal of Diabetes 35:5, pages 518-527.
Crossref
Crossref
Y. Wang, L. Li, M. Yang, H. Liu, G. Boden & G. Yang. (2011) Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials. Diabetes, Obesity and Metabolism 13:11, pages 972-981.
Crossref
Crossref
G. E. Umpierrez, T. Blevins, J. Rosenstock, C. Cheng, J. H. Anderson & E. J. BastyrIIIIII. (2011) The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes, Obesity and Metabolism 13:5, pages 418-425.
Crossref
Crossref
Yehuda Handelsman, Jeffrey I. Mechanick, Lawrence Blonde, George Grunberger, Zachary T. Bloomgarden, George A. Bray, Samuel Dagogo-Jack, Jaime A. Davidson, Daniel Einhorn, Om Ganda, Alan J. Garber, Irl B. Hirsch, Edward S. Horton, Faramarz Ismail-Beigi, Paul S. Jellinger, Kenneth L. Jones, Lois Jovanovič, Harold Lebovitz, Philip Levy, Etie S. Moghissi, Eric A. Orzeck, Aaron I. Vinik, Kathleen L. Wyne, Alan J. Garber, Daniel L. Hurley & Farhad Zangeneh. (2011) American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. Endocrine Practice 17, pages 1-53.
Crossref
Crossref
Baptist Gallwitz, Michael Böhmer, Thomas Segiet, Andrea Mölle, Karsten Milek, Bernd Becker, Karin Helsberg, Helmut Petto, Natalie Peters & Oliver Bachmann. (2011) Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes. Diabetes Care 34:3, pages 604-606.
Crossref
Crossref
Matteo Monami, Francesco Cremasco, Caterina Lamanna, Claudia Colombi, Carla Maria Desideri, Iacopo Iacomelli, Niccolò Marchionni & Edoardo Mannucci. (2011) Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials. Experimental Diabetes Research 2011, pages 1-10.
Crossref
Crossref
Deepson S Shyangdan, Pamela L Royle, Christine Clar, Pawana Sharma & Norman R Waugh. (2010) Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocrine Disorders 10:1.
Crossref
Crossref
Angelos Kyriacou & Abu Baker Ahmed. (2010) Exenatide Use in the Management of Type 2 Diabetes Mellitus. Pharmaceuticals 3:8, pages 2554-2567.
Crossref
Crossref
Joseph A. Aloi & Anthony L. McCall. 2010. Textbook of Diabetes. Textbook of Diabetes
494
513
.
Aashish G. SamatAmit BhargavaVasantha Reddy. (2010) A Review of Exenatide in the Treatment of Type 2 Diabetes Mellitus. Clinical Medicine Insights: Therapeutics 2, pages CMT.S3489.
Crossref
Crossref
David Russell-Jones. (2010) Current developments in the treatment of diabetes: the incretin therapies. The British Journal of Diabetes & Vascular Disease 10:1, pages 21-30.
Crossref
Crossref
. (2009) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:9.
Crossref
Crossref
CMB Edwards & PH Winocour. (2009) ABCD position statement on incretin mimetics and DPP‐4 inhibitors ‐2009. Practical Diabetes International 26:5, pages 191-194.
Crossref
Crossref